Jagsonpal Pharmaceuticals Ltd vs Supriya Lifescience Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 10, 2026

Key Highlights

The Latest Trading Price of Jagsonpal Pharmaceuticals Ltd is ₹ 217.9 as of 08 May 15:30 . The P/E Ratio of Jagsonpal Pharmaceuticals Ltd changed from 12.2 on March 2021 to 25.9 on March 2025 . This represents a CAGR of 16.25% over 5 yearsThe P/E Ratio of Supriya Lifescience Ltd changed from 26.1 on March 2022 to 31.4 on March 2025 . This represents a CAGR of 4.73% over 4 years The Market Cap of Jagsonpal Pharmaceuticals Ltd changed from ₹ 208.41 crore on March 2021 to ₹ 1433 crore on March 2025 . This represents a CAGR of 47.06% over 5 yearsThe Market Cap of Supriya Lifescience Ltd changed from ₹ 3967 crore on March 2022 to ₹ 5903 crore on March 2025 . This represents a CAGR of 10.45% over 4 years The revenue of Jagsonpal Pharmaceuticals Ltd for the Mar '26 is ₹ 67.37 crore as compare to the Dec '25 revenue of ₹ 75.92 crore. This represent the decline of -11.26% The revenue of Supriya Lifescience Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 209.05 crore. This represent the decline of -100% The ebitda of Jagsonpal Pharmaceuticals Ltd for the Mar '26 is ₹ 14.33 crore as compare to the Dec '25 ebitda of ₹ 17.16 crore. This represent the decline of -16.49% The ebitda of Supriya Lifescience Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 74.24 crore. This represent the decline of -100% The net profit of Jagsonpal Pharmaceuticals Ltd changed from ₹ 5.33 crore to ₹ 8.76 crore over 8 quarters. This represents a CAGR of 28.20% The net profit of Supriya Lifescience Ltd changed from ₹ 44.64 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of -100.00% The Dividend Payout of Jagsonpal Pharmaceuticals Ltd changed from 15.36 % on March 2021 to 29.99 % on March 2025 . This represents a CAGR of 14.32% over 5 yearsThe Dividend Payout of Supriya Lifescience Ltd changed from 3.2 % on March 2021 to 4.28 % on March 2025 . This represents a CAGR of 5.99% over 5 years .

About Jagsonpal Pharmaceuticals Ltd

Promoted by Rajpal Singh Kochhar in August, 1978, Jagsonpal Pharmaceuticals Limited is engaged in the manufacture and marketing bulk drugs and pharmaceuticals at its plant at Faridabad in Haryana.
The Company has adopted the strategy of clubbing all its products in seven groups for effective marketing and reducing costs.
Simultaneously, it has geared up to set up an ultra modern multi-purpose basic drugs and formulation plant through its subsidiary, Jagsonpal Exports India Pvt Ltd. The company has a strategic alliance with Fidia Spa, Italy; and B Spofola, Czechoslovakia; to manufacture sophisticated drugs in India.
It has tied up with another Israel-based company, Makhteshim Chemical Works, for acquiring the marketing rights of an anti-oxidant product.
In 1994, the company has also promoted Aresco Financial Services, a new financial company.

About Supriya Lifescience Ltd

Supriya Lifescience Limited was initially constituted on October 29, 1985, as a 'Partnership Firm under the name M/s Supriya Chemicals'.
The Partnership Firm was last re-constituted pursuant to a Partnership Deed dated November 30, 2007.
Upon the conversion of M/s Supriya Chemicals' the Partnership Firm into a Public Limited Company, the Company got incorporated as Supriya Lifescience Limited' vide certified on March 26, 2008 by the Registrar of Companies, Mumbai. The Company commenced operations in April, 2008.
It is engaged in manufacturing and export of active pharmaceutical ingredients (APIs).
The company is one of the key Indian manufacturers and suppliers of active pharmaceuticals ingredients,with a focus on research and development.

FAQs for the comparison of Jagsonpal Pharmaceuticals Ltd and Supriya Lifescience Ltd

Which company has a larger market capitalization, Jagsonpal Pharmaceuticals Ltd or Supriya Lifescience Ltd?

Market cap of Jagsonpal Pharmaceuticals Ltd is 1,462 Cr while Market cap of Supriya Lifescience Ltd is 5,696 Cr

What are the key factors driving the stock performance of Jagsonpal Pharmaceuticals Ltd and Supriya Lifescience Ltd?

The stock performance of Jagsonpal Pharmaceuticals Ltd and Supriya Lifescience Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Jagsonpal Pharmaceuticals Ltd and Supriya Lifescience Ltd?

As of May 10, 2026, the Jagsonpal Pharmaceuticals Ltd stock price is INR ₹217.9. On the other hand, Supriya Lifescience Ltd stock price is INR ₹707.8.

How do dividend payouts of Jagsonpal Pharmaceuticals Ltd and Supriya Lifescience Ltd compare?

To compare the dividend payouts of Jagsonpal Pharmaceuticals Ltd and Supriya Lifescience Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.